Literature DB >> 22310251

Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.

Arpakorn Kositwattanarerk1, Myungmi Oh, Takashi Kudo, Yasushi Kiyono, Tetsuya Mori, Yuichi Kimura, Rikiya Maruyama, Yasuhisa Fujibayashi, Shigeharu Fujieda, Hidehiko Okazawa.   

Abstract

PURPOSE: [⁶²Cu]-diacetyl-bis(N4-methlythiosemicarbazone) (Cu-ATSM) was used to delineate hypoxic tissue in head-and-neck cancer, and its distribution was compared with that of ¹⁸F-FDG.
MATERIALS AND METHODS: Thirty patients with head-and-neck cancer underwent Cu-ATSM and FDG PET within a 1 week interval. Accumulation of tracer for each PET image was converted to SUV. After coregisteration of PET images with individual anatomic images, multiple small ROIs were drawn on the tumor mass and applied to both PET images. SUV values were obtained for all ROIs (SUV(roi)), and the SUV(roi) regression lines between Cu-ATSM and FDG of each tumor were determined.
RESULTS: The SUV mean of Cu-ATSM was lower than that of FDG for both squamous cell carcinoma (SCC) and adenocarcinoma (P < 0.05). In 27 patients with SCC, Cu-ATSM accumulated higher in the peripheral region than in the center of the tumor, and FDG showed the other tendency. Thus, the relationship of the SUV(roi) for Cu-ATSM and FDG showed a negative correlation in SCC. However, 3 adenocarcinoma cases showed similar and homogenous accumulation in the tumor mass with a positive SUV(roi) correlation for the 2 tracers. The regression slope means were -0.12 ± 0.08 for SCC (n = 27) and 0.28 ± 0.12 (n = 3) for adenocarcinoma.
CONCLUSION: In patients with head-and-neck cancer, intratumoral distribution of Cu-ATSM and FDG showed a negative correlation in SCC and a positive correlation in adenocarcinoma. The 2 tracers represented different pathophysiological microenvironments in different tumors, suggesting that noninvasive hypoxic tissue imaging with Cu-ATSM would be beneficial in the pretreatment evaluation of head-and-neck cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310251     DOI: 10.1097/RLU.0b013e31823eaadb

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

Review 1.  Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

Authors:  Suzanne E Lapi; Jason S Lewis; Farrokh Dehdashti
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

2.  [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation.

Authors:  Fang Xie; Weijun Wei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-10       Impact factor: 10.057

Review 3.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.

Authors:  Alexander Speer; Tej B Shrestha; Stefan H Bossmann; Randall J Basaraba; Gregory J Harber; Suzanne M Michalek; Michael Niederweis; Olaf Kutsch; Frank Wolschendorf
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

5.  Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.

Authors:  Maxwell G Handley; Rodolfo A Medina; Erika Mariotti; Gavin D Kenny; Karen P Shaw; Ran Yan; Thomas R Eykyn; Philip J Blower; Richard Southworth
Journal:  J Nucl Med       Date:  2014-01-13       Impact factor: 10.057

6.  Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.

Authors:  Tetsuya Tsujikawa; Satoko Asahi; Myungmi Oh; Yoshitaka Sato; Norihiko Narita; Akira Makino; Tetsuya Mori; Yasushi Kiyono; Tatsuro Tsuchida; Hirohiko Kimura; Shigeharu Fujieda; Hidehiko Okazawa
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

7.  Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis.

Authors:  Kamilla Westarp Zornhagen; Anders E Hansen; Jytte Oxboel; Andreas E Clemmensen; Henrik H El Ali; Annemarie T Kristensen; Andreas Kjær
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.